130 related articles for article (PubMed ID: 8580000)
1. Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma.
Kuliszkiewicz-Janus M; Baczyński S
NMR Biomed; 1995 May; 8(3):127-32. PubMed ID: 8580000
[TBL] [Abstract][Full Text] [Related]
2. Treatment-induced changes in 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia.
Kuliszkiewicz-Janus M; Baczyński S
Biochim Biophys Acta; 1997 Feb; 1360(1):71-83. PubMed ID: 9061042
[TBL] [Abstract][Full Text] [Related]
3. Application of 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas.
Kuliszkiewicz-Janus M; Baczyński S
Magn Reson Med; 1996 Apr; 35(4):449-56. PubMed ID: 8992193
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow transplantation in the course of hematological malignancies--follow-up study in blood serum by 31P MRS.
Kuliszkiewicz-Janus M; Baczyński S; Jurczyk A
Med Sci Monit; 2004 Aug; 10(8):CR485-92. PubMed ID: 15278000
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
6. Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low- and high-density lipoprotein to human platelets.
Engelmann B; Kögl C; Kulschar R; Schaipp B
Biochem J; 1996 May; 315 ( Pt 3)(Pt 3):781-9. PubMed ID: 8645158
[TBL] [Abstract][Full Text] [Related]
7. Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers.
Kuliszkiewicz-Janus M; Janus W; Baczyński S
Anticancer Res; 1996; 16(3B):1587-94. PubMed ID: 8694531
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
9. Fast transmission of alterations in plasma phosphatidylcholine/sphingomyelin ratio and lyso phosphatidylcholine levels into changes of red blood cell membrane phospholipid composition after low density lipoprotein apheresis.
Kulschar R; Engelmann B; Bräutigam C; Duhm J; Thiery J; Richter WO
Eur J Clin Invest; 1995 Apr; 25(4):258-65. PubMed ID: 7601201
[TBL] [Abstract][Full Text] [Related]
10. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of multiple myeloma].
Golenkov AK
Sov Med; 1991; (3):43-6. PubMed ID: 1882290
[No Abstract] [Full Text] [Related]
12. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
[No Abstract] [Full Text] [Related]
15. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
16. [The influence of verapamil on platelet function in patients with multiple myeloma].
Sokołowska B; Dmoszyńska A; Walter-Croneck A; Wojtaszko M
Pol Merkur Lekarski; 1997 Feb; 2(8):109-10. PubMed ID: 9538652
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies for plasma cell myeloma.
Smith L; Alexanian R
CA Cancer J Clin; 1985; 35(4):214-20. PubMed ID: 3926257
[No Abstract] [Full Text] [Related]
18. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
[TBL] [Abstract][Full Text] [Related]
19. [Results with the use of the M-2 protocol in plasmacytoma].
Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
[TBL] [Abstract][Full Text] [Related]
20. Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy.
van Hoeven KH; Reed LJ; Factor SM
Cancer; 1990 Oct; 66(7):1472-4. PubMed ID: 2207998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
